Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Strategic Partners
Pipeline
Overview
Hemostasis
Complement
Expanded Access Policy
Science
Overview
Publications
Clinical Trials
Overview
MAA-304
MAA-202
CB 4332
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Careers
Career Opportunities
Benefits
Values
Contact
AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT
Post navigation
Previous:
Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (Activated) An Engineered FVIIa In Hemophilia With Inhibitors -Pharmacokinetics, Pharmacodynamics, Safety and Efficacy
Next:
CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD
X
Previous
Next
